Kazia reports successful stage 1 completion of the EVT801 Phase 1 clinical trial in advanced cancer patients  
    Professor takes big step in fighting cancer which claimed his daughter  
    Parents of kids with DIPG say funding for trial urgently needed  
    Kazia provides overview of Paxalisib related presentations from the Society of Neuro-Oncology 2023 Annual Meeting  
    Kazia Therapeutics appoints Dr John Friend as new CEO  
    Kazia Therapeutics to present new pipeline molecule data at AACR 2023  
    Kazia Therapeutics forms clinical collaboration for Australian Phase 2 study of paxalisib, targeting childhood cancers  
    Kazia Therapeutics raises A$7 million to fund R&D pipeline  
    After a successful $4.5 million cap raise and with cancer trial results to come, Kazia is optimistic for 2023  
    ASX rose 6.2% in January: Aus shares closed the day 0.07% lower  
    High cost of living causes a fall in retail sales: ASX up 0.22% at noon  
    Kazia Therapeutics CEO talks $4.5 million capital raise  
    Kazia Therapeutics raising $4.5 million in placement; launches SPP  
    Kazia Therapeutics exploring use of lead asset in other cancers: Edison Investment Research  
    Kazia Therapeutics files patent as it continues to work with QIMT on cancer research  
    SMH: ‘Waiting for your child to die is not an option’  
    Kazia Therapeutics’ upcoming top-line data for EVT801 expected to be a share price catalyst: Edison Investment Research  
    Kazia Therapeutics talks positive pre-clinical data for EVT801  
    Almost all sectors higher: Aus shares close up 1%  
    ASX opens to 7-month high after Powells positive news: Aus shares up 0.8%  
    Kazia Therapeutics welcomes publication of positive pre-clinical data for EVT801 in peer-reviewed cancer research journal  
    ASX increases slightly ahead of today's interest rate rise: Aus shares 0.3% higher at noon  
    US tech earnings weighing down Aus tech sector: ASX falls 0.62% at noon  
    Stocks of the Hour: Kazia Therapeutics, Green Technology Metals, Winsome Resources  
    Kazia Therapeutics’ (ASX:KZA) paxalisib shows positive signals against preclinical melanoma models  
    Kazia Therapeutics takes Phase 2 study of paxalisib international; opens two sites in Australia  
    Stockhead Health and Biotech Investment Guide  
    Stocks of the Hour: Kazia Therapeutics, Mesoblast, BHP &Oz Minerals  
    ASX edges lower in morning trading, reporting season kicks off: Aus shares down 0.2% at noon  
    Kazia Therapeutics gives progress report on GBM AGILE pivotal study for glioblastoma  
    Kazia Therapeutics' promising data on treatment targeting brain metastases to be presented at conference  
    Kazia Therapeutics forms new Scientific Advisory Board with world-leading experts in brain cancer  
    Tech snaps 4-day winning streak, Iron ore miners rebound: ASX closes 0.8% higher  
    Australia trade surplus hits record high, Chalice Mining soars on discovery: ASX up 0.2% at noon  
    Stocks of the Hour: Elsight, Kazia Therapeutics, Chalice Mining  
    Kazia Therapeutics gains US FDA Rare Paediatric Disease Designation for paxalisib in rare form of childhood brain cancer  
    Kazia Therapeutics continues to make good progress on cancer treatment assets  
    Kazia Therapeutics secures orphan drug designation for treatment of AT/RT tumours with paxalisib  
    Stocks of the Hour: Kazia Therapeutics, Westgold Resources &Lake Resources  
    Kazia Therapeutics welcomes presentation of positive paxalisib data at international symposium  
    Kazia onto next chapter in Phase 2 brain metastases trial  
    Kazia Therapeutics’ Phase 2 paxalisib study moves to expansion stage in breast cancer brain metastases cohort  
    Kazia Therapeutics’ paxalisib now the subject of multi-drug platform study at the University Hospital, Zurich  
    Sector Watch: Healthcare - M&Afever on the cards?  
    Nasdaq jumps as Dow falls, Immutep, Antisense, Pushpay, AGL, Star on watch: ASX poised to open lower  
    Kazia Therapeutics and its flagship asset have made significant progress against brain cancers: Pitt Street Research  
    Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting  
    Kazia Therapeutics establishes ‘at the market’ equity program  
    Kazia Therapeutics completes Phase 2 study of glioblastoma drug Paxalisib; data to follow at conference  
    Kazia Therapeutics encouraged by “promising data” on its cancer pipeline presented at AACR meeting in New Orleans  
    Kazia Therapeutics initiates Phase II study of paxalisib for newly diagnosed and recurrent glioblastoma  
    Kazia Therapeutics delivers on plans with two promising assets in human trials  
    Kazia Therapeutics appoints US-based CFO to assist global market expansion  
    Kazia Therapeutics' clinical paxalisib data maintains Speculative Buy rating from Bell Potter  
    Kazia Therapeutics (ASX:KZA) announces positive results for brain cancer drug  
    ASX up, Berkshire billionaire gives his views on crypto and will BHP benefit from rising iron ore prices?  
    Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up  
    Kazia Therapeutics expands further in North America with Toronto glioblastoma study  
    Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO  
    Kazia Therapeutics welcomes start of PNOC study in childhood brain cancer, first patient enrolled  
    Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial  
    Kazia Therapeutics enrols first patient to phase I clinical trial of EVT801 cancer therapy  
    Kazia Therapeutics gets boost with ‘buy’ call from Maxim Group and valuation upgrade from Edison  
    Kazia Therapeutics’ paxalisib program data garners increased target share price of A$2.83 from Edison  
    Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference  
    Kazia Therapeutics receives full regulatory approval for EVT801 phase 1 study  
    Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial  
    Kazia Therapeutics (ASX:KZA) glioblastoma Phase II trial results